← Back to Search

F18-Fluoride PET/CT for Bone Metastases

Phase 3
Waitlist Available
Led By Johannes Czernin, MD
Research Sponsored by American College of Radiology - Image Metrix
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Summary

The primary objective is to compare the diagnostic performance of 18F- Fluoride PET/CT scanning to that of conventional bone scanning for detecting cancer that has spread to the bone (bone metastasis). The intent of the study is to determine whether 18F-Fluoride PET/CT will lead to improved treatment and patient outcomes.

Eligible Conditions
  • Bone Metastases

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Analysis of the diagnostic performance of [18F]NaF fluoride PET/CT scanning

Side effects data

From 2012 Phase 3 trial • 72 Patients • NCT01641237
2%
Mouth Ulceration
2%
Cough
2%
Nasopharyngitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
NaF Dentifrice (1426 ppmF)
Placebo Dentifrice (0 ppmF)
NaF Dentifrice (250 ppmF)
NaF Dentifrice (1150 ppmF)

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: F18-Fluoride PET/CTExperimental Treatment1 Intervention
Patients without known bone metastases who are newly diagnosed with ≥ stage 3 breast cancer, ≥ stage 3 lung cancer, or ≥ stage 2 prostate cancer (and/or PSA \>10 micrograms/L), including patient with recurrent breast, lung or prostate cancer; Patient is scheduled to undergo a conventional bone scan
Group II: TC-MDP Bone ScanActive Control1 Intervention
Patients without known bone metastases who are newly diagnosed with ≥ stage 3 breast cancer, ≥ stage 3 lung cancer, or ≥ stage 2 prostate cancer (and/or PSA \>10 micrograms/L), including patient with recurrent breast, lung or prostate cancer; Patient is scheduled to undergo a conventional bone scan

Find a Location

Who is running the clinical trial?

American College of Radiology - Image MetrixLead Sponsor
2 Previous Clinical Trials
279 Total Patients Enrolled
World Molecular Imaging SocietyUNKNOWN
Johannes Czernin, MDPrincipal InvestigatorWorld Molecular Imaging Society
8 Previous Clinical Trials
1,484 Total Patients Enrolled
~33 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top